Mercury Laboratories Ltd Share Price & Stock Analysis

Mercury Laboratories Ltd (BSE: 538964) is a Vadodara, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹90 Cr, it ranks #3,333 by market cap among the 6,197 Indian listed companies on FinBizNet, and #70 of 86 in Medicinal Chemicals and Botanical Products. At ₹777.70 (as of 16 Nov 2026), the share price is 16.2% below its 52-week high of ₹928.50 and 25.3% above its 52-week low of ₹620.55. The share price is down 8.3% over one year and up 2.7% over three months.

Key Metrics

Current Price₹777.70
Market Cap₹90 Cr
BSE Code538964
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio18.6
Return on Equity8.66%
Return on Assets4.90%
52-Week Range₹620.55 – ₹928.50
1-Year Price Change-8.3%
3-Month Price Change+2.7%
Beta (1Y)0.52
Dividend Yield0.47%
HeadquartersVadodara, Gujarat
Websitewww.mercurylabs.com

Shareholding and Delivery

Delivery averaged 92.5% of traded volume across 13 BSE sessions (21 Oct 2026 – 13 Nov 2026).

About Mercury Laboratories Ltd

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergic, steroids, urinary system, uterine stimulant, and other drugs; and formulations, including tablets, oral liquids, injections, small volume parenterals, and eye/ear drops. It also provides pharmaceutical products for PCOS and uterine disorders, galactagogue, haemostat, iron and vitamins, pain management, preterm labor management, antiemetic, PPI; vitamin K1, zinc supplement, antiallergic, vitamin D3, digestive enzyme, promolact, antipyretic, and

Products and Services

1. Pharmaceuticals Products-This segment develops, manufactures, markets, distributes, and sells pharmaceuticals, medicinal drugs, and formulations for mother and child healthcare.

Business Segments

1. Pharmaceuticals Products-100%

Mercury Laboratories Ltd vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Mercury Laboratories Ltd₹90 Cr18.68.66%—-8.3%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Mercury Laboratories Ltd?

Mercury Laboratories Ltd is trading at ₹777.70, with a market capitalisation of ₹90 Cr.

Which sector does Mercury Laboratories Ltd belong to?

Mercury Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Mercury Laboratories Ltd?

Mercury Laboratories Ltd has a P/E of 18.6 and a return on equity of 8.66%.

What is the stock symbol of Mercury Laboratories Ltd?

Mercury Laboratories Ltd is listed on the BSE under the scrip code 538964.

How has Mercury Laboratories Ltd's share price moved over the past year?

Mercury Laboratories Ltd's share price is down 8.3% over one year and up 2.7% over three months. Its 52-week range is ₹620.55 to ₹928.50.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.